Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (8): 1067-1072.
• Frontier, Exploration, and Controversy • Previous Articles Next Articles
Received:2026-07-23
Online:2026-08-31
Published:2026-09-28
| [1] Seto W K, Lo Y R, Pawlotsky J M, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392(10161): 2313-2324. [2] Choi W M, Seto W K. Unraveling the metabolic thread: type 2 diabetes and fibrosis in chronic hepatitis B with steatosis[J]. Hepatology, 2026, 83(5): 1046-1048. [3] Liguori A, Zoncapè M, Casazza G, et al. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2025, 10(4): 332-349. [4] EASL Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2025, 83(2): 502-583. [5] Li J, Xu L, Rui F, et al. Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naÏve chronic hepatitis B patients with concurrent hepatic steatosis[J]. Hepatology, 2026, 83(5): 1273-1286. [6] Luo Y, Li R, Kang J, et al. Chronic hepatitis B with type 2 diabetes mellitus: association between glycemic control and liver fibrosis[J]. World J Diabetes, 2025, 16(7): 107256. [7] Mederacke I, Filliol A, Affo S, et al. The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver[J]. Sci Transl Med, 2022, 14(639): eabe5795. [8] Genitsaridi I, Salpea P, Salim A, et al. 11th edition of the IDF diabetes atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050[J]. Lancet Diabetes Endocrinol, 2026, 14(2): 149-156. [9] Lei S, Chen S, Zhao X, et al. Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China[J]. Hepatol Int, 2020, 14(5): 743-753. [10] Lee J G, Lee S, Kim Y J, et al. Association of chronic viral hepatitis B with insulin resistance[J]. World J Gastroenterol, 2012, 18(42): 6120-6126. [11] Mavrogiannaki A, Karamanos B, Manesis E K, et al. Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study[J]. J Viral Hepat, 2009, 16(6): 430-436. [12] Lee W G, Wells C I, McCall J L, et al. Prevalence of diabetes in liver cirrhosis: a systematic review and meta-analysis[J]. Diabetes Metab Res Rev, 2019, 35(6): e3157. [13] Jia W, Chan J C, Wong T Y, et al. Diabetes in China: epidemiology, pathophysiology and multi-omics[J]. Nat Metab, 2025, 7(1): 16-34. [14] Huang S C, Kao J H. The interplay between chronic hepatitis B and diabetes mellitus: a narrative and concise review[J]. Kaohsiung J Med Sci, 2024, 40(1): 6-10. [15] Mak L Y, Hui R W, Lee C H, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes[J]. Hepatology, 2023, 77(2): 606-618. [16] Bo T, Gao L, Yao Z, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease[J]. Cell Metab, 2024, 36(5): 947-968. [17] Hardy T, Oakley F, Anstee Q M, et al. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum[J]. Annu Rev Pathol, 2016, 11: 451-496. [18] Filali-Mouncef Y, Hunter C, Roccio F, et al. The ménage à trois of autophagy, lipid droplets and liver disease[J]. Autophagy, 2022, 18(1): 50-72. [19] Du K, Jun J H, Dutta R K, et al. Plasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology[J]. Hepatol Commun, 2024, 8(5). [20] Odagiri N, Matsubara T, Sato-Matsubara M, et al. Anti-fibrotic treatments for chronic liver diseases: the present and the future[J]. Clin Mol Hepatol, 2021, 27(3): 413-424. [21] Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55. [22] Lyu C, Kong W, Liu Z, et al. Advanced glycation end-products as mediators of the aberrant crosslinking of extracellular matrix in scarred liver tissue[J]. Nat Biomed Eng, 2023, 7(11): 1437-1454. [23] Dong H, Zhang Y, Huang Y, et al. Pathophysiology of RAGE in inflammatory diseases[J]. Front Immunol, 2022, 13: 931473. [24] Lim S G, Baumert T F, Boni C, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(4): 238-253. [25] Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(10): 633-646. [26] Sharma S, Le Guillou D, Chen J Y. Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(10): 662-678. [27] Witcoski Junior L, de Lima J D, Somensi A G, et al. Metabolic reprogramming of macrophages in the context of type 2 diabetes[J]. Eur J Med Res, 2024, 29(1): 497. [28] Gray V, Chen W, Tan R J Y, et al. Hyperglycemia-triggered lipid peroxidation destabilizes STAT4 and impairs anti-viral Th1 responses in type 2 diabetes[J]. Cell Metab, 2024, 36(12): 2511-2527.e7. [29] Cheng J Y, Shan G Y, Wan H, et al. MIF/CD74 axis in hepatic stellate cells mediates HBV-related liver fibrosis[J]. Int Immunopharmacol, 2025, 147: 113929. [30] Mantovani A, Byrne C D, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review[J]. Lancet Gastroenterol Hepatol, 2022, 7(4): 367-378. [31] Jin Z, Yin R, Yuan Y, et al. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRα-mediated synthesis of lipids and bile acids[J]. Biochem Pharmacol, 2024, 223: 116167. [32] Shen Y, Cheng L, Xu M, et al. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis[J]. Metabolism, 2023, 146: 155657. [33] Lin J, Huang Y, Xu B, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial[J]. Bmj, 2025, 389: e083735. [34] Lee C H, Mak L Y, Tang E H, et al. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: a territory-wide cohort study in Hong Kong[J]. Hepatology, 2023, 78(5): 1569-1580. [35] Yabut J M, Drucker D J. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease[J]. Endocr Rev, 2023, 44(1): 14-32. [36] Zafer M, Tavaglione F, Romero-Gómez M, et al. Review article: GLP-1 receptor agonists and glucagon/GIP/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD[J]. Aliment Pharmacol Ther, 2025, 61(12): 1872-1888. [37] Wang M W, Lu L G. Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective[J]. J Clin Transl Hepatol, 2025, 13(1): 47-61. [38] Allam M M, el Gazzar W B. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model[J]. Arch Physiol Biochem, 2018, 124(1): 10-17. [39] Engstr?m A, Wintzell V, Melbye M, et al. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a scandinavian cohort study[J]. Hepatology, 2024, 79(6): 1401-1411. [40] Jara M, Norlin J, Kjær M S, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis[J]. Nat Med, 2025, 31(9): 3128-3140. [41] Do A, Zahrawi F, Mehal W Z. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)[J]. Nat Rev Drug Discov, 2025, 24(3): 171-189. [42] Akkiz H, Gieseler R K, Canbay A. Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells[J]. Int J Mol Sci, 2024, 25(14). [43] Zhou Z, Jin R, Gu Y, et al. Therapeutic targeting of PPARγ in nonalcoholic fatty liver disease: efficacy, safety, and drug development[J]. Drug Des Devel Ther, 2025, 19: 7293-7319. [44] Morán-Salvador E, Titos E, Rius B, et al. Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells[J]. J Hepatol, 2013, 59(5): 1045-1053. [45] Tao L, Wu L, Zhang W, et al. Peroxisome proliferator-activated receptor γ inhibits hepatic stellate cell activation regulated by miR-942 in chronic hepatitis B liver fibrosis[J]. Life Sci, 2020, 253: 117572. [46] Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial[J]. Ann Intern Med, 2016, 165(5): 305-315. [47] Petta S, Cammà C, Di Marco V, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection[J]. Liver Int, 2011, 31(4): 507-515. [48] EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update[J]. J Hepatol, 2021, 75(3): 659-689. [49] Kim M N, An J, Kim E H, et al. Vibration-controlled transient elastography for significant fibrosis in treatment-naÏve chronic hepatitis B patients: a systematic review and meta-analysis[J]. Clin Mol Hepatol, 2024, 30(Suppl): S106-S116. [50] 贾婷, 杨晓冬, 高斯媛, 等. 恩替卡韦治疗慢性乙肝并2型糖尿病疗效及肾脏安全性研究[J]. 云南医药, 2024, 45(6): 17-20. [51] Arita V A, Cabezas M C, Hernández Vargas J A, et al. Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials[J]. BMC Med, 2025, 23(1): 502. [52] Hallsworth K, Adams L A. Lifestyle modification in NAFLD/NASH: Facts and figures[J]. JHEP Rep, 2019, 1(6): 468-479. [53] Cuthbertson D J, Keating S E, Pugh C J A, et al. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease[J]. Liver Int, 2024, 44(9): 2368-2381. [54] EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3): 492-542. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
